155 related articles for article (PubMed ID: 25837471)
21. Evolution of availability of curcumin inside poly-lactic-co-glycolic acid nanoparticles: impact on antioxidant and antinitrosant properties.
Betbeder D; Lipka E; Howsam M; Carpentier R
Int J Nanomedicine; 2015; 10():5355-66. PubMed ID: 26345627
[TBL] [Abstract][Full Text] [Related]
22. Micelle-templated, poly(lactic-
Nabar GM; Mahajan KD; Calhoun MA; Duong AD; Souva MS; Xu J; Czeisler C; Puduvalli VK; Otero JJ; Wyslouzil BE; Winter JO
Int J Nanomedicine; 2018; 13():351-366. PubMed ID: 29391794
[TBL] [Abstract][Full Text] [Related]
23. Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres.
Ghassemi AH; van Steenbergen MJ; Barendregt A; Talsma H; Kok RJ; van Nostrum CF; Crommelin DJ; Hennink WE
Pharm Res; 2012 Jan; 29(1):110-20. PubMed ID: 21744173
[TBL] [Abstract][Full Text] [Related]
24. Preparation and Characterization of PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation.
Manish M; Bhatnagar R; Singh S
Methods Mol Biol; 2016; 1404():669-681. PubMed ID: 27076329
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems.
Schwendeman SP
Crit Rev Ther Drug Carrier Syst; 2002; 19(1):73-98. PubMed ID: 12046892
[TBL] [Abstract][Full Text] [Related]
26. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
27. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited.
Xu P; Gullotti E; Tong L; Highley CB; Errabelli DR; Hasan T; Cheng JX; Kohane DS; Yeo Y
Mol Pharm; 2009; 6(1):190-201. PubMed ID: 19035785
[TBL] [Abstract][Full Text] [Related]
28. The role of the cyclic imide in alternate degradation pathways for asparagine-containing peptides and proteins.
Dehart MP; Anderson BD
J Pharm Sci; 2007 Oct; 96(10):2667-85. PubMed ID: 17518358
[TBL] [Abstract][Full Text] [Related]
29. Pairing-Enhanced Regioselectivity: Synthesis of Alternating Poly(lactic-
Lu Y; Coates GW
J Am Chem Soc; 2023 Oct; 145(41):22425-22432. PubMed ID: 37793193
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and characterization of a poly(lactic-co-glycolic acid) core + poly(N-isopropylacrylamide) shell nanoparticle system.
Kosinski AM; Brugnano JL; Seal BL; Knight FC; Panitch A
Biomatter; 2012; 2(4):195-201. PubMed ID: 23507885
[TBL] [Abstract][Full Text] [Related]
31. Peptide acylation by poly(alpha-hydroxy esters).
Lucke A; Kiermaier J; Göpferich A
Pharm Res; 2002 Feb; 19(2):175-81. PubMed ID: 11883645
[TBL] [Abstract][Full Text] [Related]
32. Protein release microparticles based on the blend of poly(D,L-lactic-co-glycolic acid) and oligo-ethylene glycol grafted poly(L-lactide).
Cho KY; Choi SH; Kim CH; Nam YS; Park TG; Park JK
J Control Release; 2001 Oct; 76(3):275-84. PubMed ID: 11578742
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of bone matrix and demineralized bone matrix incorporated PLGA matrices for bone repair.
Jayasuriya AC; Ebraheim NA
J Mater Sci Mater Med; 2009 Aug; 20(8):1637-44. PubMed ID: 19330524
[TBL] [Abstract][Full Text] [Related]
34. Computational Analysis of the Mechanism of Nonenzymatic Peptide Bond Cleavage at the C-Terminal Side of an Asparagine Residue.
Kato K; Nakayoshi T; Ishikawa Y; Kurimoto E; Oda A
ACS Omega; 2021 Nov; 6(44):30078-30084. PubMed ID: 34778679
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid oligomers: Part II. Biodegradation and drug delivery application.
Wang N; Wu XS
J Biomater Sci Polym Ed; 1997; 9(1):75-87. PubMed ID: 9505204
[TBL] [Abstract][Full Text] [Related]
36. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres.
Cleland JL; Mac A; Boyd B; Yang J; Duenas ET; Yeung D; Brooks D; Hsu C; Chu H; Mukku V; Jones AJ
Pharm Res; 1997 Apr; 14(4):420-5. PubMed ID: 9144725
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: Part III. Drug delivery application.
Wu XS
Artif Cells Blood Substit Immobil Biotechnol; 2004; 32(4):575-91. PubMed ID: 15974184
[TBL] [Abstract][Full Text] [Related]
38. Biocompatibility and enhanced osteogenic differentiation of human mesenchymal stem cells in response to surface engineered poly(D,L-lactic-co-glycolic acid) microparticles.
Rogers CM; Deehan DJ; Knuth CA; Rose FR; Shakesheff KM; Oldershaw RA
J Biomed Mater Res A; 2014 Nov; 102(11):3872-82. PubMed ID: 24339408
[TBL] [Abstract][Full Text] [Related]
39. Minimizing acylation of peptides in PLGA microspheres.
Zhang Y; Schwendeman SP
J Control Release; 2012 Aug; 162(1):119-26. PubMed ID: 22546683
[TBL] [Abstract][Full Text] [Related]
40. Redefining the importance of polylactide-co-glycolide acid (PLGA) in drug delivery.
Chavan YR; Tambe SM; Jain DD; Khairnar SV; Amin PD
Ann Pharm Fr; 2022 Sep; 80(5):603-616. PubMed ID: 34896382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
